Since founded in 2016,  

Theracion Biomedical has concentrated on the development of novel topical hemostats. 4 R&D projects for new topical hemostats’ development have been funded with grants from the Ministry of SMEs and Startups, Korea for approximately US$1.1 million. 

In 2019, 

The company acquired TIPS (Accelerator Investment-Driven Tech Incubator Program for Startup) program, a government grant for tech start-ups which is designed to identify and nurture the most promising startups with innovative ideas and groundbreaking technologies. It offers seamless service encompassing angel investor networking, incubating, mentoring/professional support and matching R&D funds. 

Tableau Wax, a newly-developed biodegradable bone hemostasis material, received KFDA approval for distribution in Korea. Certification of CE(MDD) and FDA 510(K) are ongoing. 

In 2020, 

Theracion Biomedical entered Pre-series stage and was funded by Hanmi Healthcare Inc., one of the leading medical device distributors in Korea with approximately US$ 1.9 million. 

OOZFIX, absorbable haemostat powder, is approved by the KFDA. OOZFIX, a proprietary patent pending technology, is a plant based hemostat containing no animal nor human components. 

Since 2021, 

Theracion Biomedical has been studying surgical sealants and adhesives and biodegradable tissue meshes/sheets as well as topical hemostats. New surgical sealants and tissue meshes/sheets will be on the market in the near future. 

In terms of animal healthcare, the company has distributors in China, Australia/New zealand, Japan as well as Korea.